A detailed history of Wellington Management Group LLP transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 7,896,632 shares of AKRO stock, worth $231 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
7,896,632
Previous 5,114,603 54.39%
Holding current value
$231 Million
Previous $120 Million 88.81%
% of portfolio
0.04%
Previous 0.02%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.45 - $29.34 $59.7 Million - $81.6 Million
2,782,029 Added 54.39%
7,896,632 $227 Million
Q2 2024

Aug 13, 2024

SELL
$18.31 - $24.62 $1.81 Million - $2.43 Million
-98,761 Reduced 1.89%
5,114,603 $120 Million
Q1 2024

May 15, 2024

BUY
$17.76 - $31.18 $92.6 Million - $163 Million
5,213,364 New
5,213,364 $132 Million
Q4 2023

Feb 12, 2024

BUY
$11.38 - $50.33 $32.8 Million - $145 Million
2,881,989 New
2,881,989 $67.3 Million
Q3 2023

Nov 14, 2023

SELL
$41.19 - $52.25 $2.98 Million - $3.77 Million
-72,244 Reduced 8.02%
828,961 $41.9 Million
Q2 2023

Aug 14, 2023

SELL
$36.89 - $56.88 $9.57 Million - $14.8 Million
-259,337 Reduced 22.35%
901,205 $42.1 Million
Q1 2023

May 12, 2023

BUY
$37.27 - $50.24 $10.6 Million - $14.3 Million
284,443 Added 32.47%
1,160,542 $44.4 Million
Q4 2022

Feb 13, 2023

BUY
$33.44 - $54.8 $2.66 Million - $4.36 Million
79,600 Added 9.99%
876,099 $48 Million
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $954,292 - $3.2 Million
94,019 Added 13.38%
796,499 $27.1 Million
Q2 2022

Aug 15, 2022

SELL
$8.0 - $15.01 $12.2 Million - $23 Million
-1,530,043 Reduced 68.53%
702,480 $6.64 Million
Q1 2022

May 16, 2022

BUY
$12.97 - $22.26 $4.61 Million - $7.92 Million
355,712 Added 18.95%
2,232,523 $31.7 Million
Q4 2021

Feb 11, 2022

SELL
$19.87 - $26.24 $606,372 - $800,766
-30,517 Reduced 1.6%
1,876,811 $39.7 Million
Q3 2021

Nov 15, 2021

BUY
$18.65 - $25.46 $4.8 Million - $6.56 Million
257,638 Added 15.62%
1,907,328 $42.6 Million
Q2 2021

Aug 16, 2021

BUY
$24.81 - $32.35 $2.64 Million - $3.44 Million
106,360 Added 6.89%
1,649,690 $40.9 Million
Q1 2021

May 17, 2021

SELL
$24.04 - $34.19 $3.06 Million - $4.35 Million
-127,180 Reduced 7.61%
1,543,330 $44.8 Million
Q4 2020

Feb 12, 2021

SELL
$25.12 - $29.89 $3.06 Million - $3.64 Million
-121,803 Reduced 6.8%
1,670,510 $43.1 Million
Q3 2020

Nov 16, 2020

BUY
$30.79 - $39.92 $54.9 Million - $71.2 Million
1,784,115 Added 21762.81%
1,792,313 $55.2 Million
Q2 2020

Aug 14, 2020

BUY
$19.25 - $26.76 $157,811 - $219,378
8,198 New
8,198 $204,000
Q1 2020

May 14, 2020

SELL
$12.8 - $27.05 $3.15 Million - $6.66 Million
-246,301 Closed
0 $0
Q4 2019

Feb 11, 2020

BUY
$17.37 - $27.27 $4.28 Million - $6.72 Million
246,301 New
246,301 $5.47 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.36B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.